Core Viewpoint - Yiling Pharmaceutical's stock has shown a significant increase this year, with a year-to-date rise of 24.44%, indicating strong market performance and investor interest [1][2]. Financial Performance - For the period from January to September 2025, Yiling Pharmaceutical reported a revenue of 5.868 billion yuan, a year-on-year decrease of 7.82%. However, the net profit attributable to shareholders reached 1 billion yuan, reflecting a substantial year-on-year growth of 80.33% [2]. Stock Market Activity - As of November 26, Yiling Pharmaceutical's stock price was 19.55 yuan per share, with a trading volume of 4.24 billion yuan and a market capitalization of 32.662 billion yuan. The stock has experienced a 3.66% increase over the past five trading days and a 20.83% increase over the past 60 days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with a net buy of 64.05 million yuan on January 6, contributing to a total buy of 233 million yuan, which accounted for 14.28% of total trading volume [1]. Shareholder Information - As of September 30, 2025, Yiling Pharmaceutical had 152,700 shareholders, a decrease of 10.22% from the previous period. The average number of circulating shares per shareholder increased by 11.38% to 9,013 shares [2]. - The company has distributed a total of 4.455 billion yuan in dividends since its A-share listing, with 1.838 billion yuan distributed in the last three years [3]. Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, Hong Kong Central Clearing Limited is the third-largest shareholder with 25.704 million shares, an increase of 8.1119 million shares from the previous period. Meanwhile, the Southern CSI 500 ETF has reduced its holdings by 256,900 shares [3].

Core Viewpoint - Jinhua Co., Ltd. has experienced a stock price increase of 13.08% year-to-date, with significant gains in recent trading periods, indicating positive market sentiment despite a slight decline on November 26 [2]. Group 1: Stock Performance - As of November 26, Jinhua's stock price was reported at 8.80 CNY per share, with a trading volume of 77.9 million CNY and a turnover rate of 2.34%, resulting in a total market capitalization of 3.285 billion CNY [1]. - The stock has seen a price increase of 8.51% over the last five trading days, 16.87% over the last 20 days, and 11.39% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Jinhua achieved a revenue of 384 million CNY, reflecting a year-on-year decrease of 8.36%, while the net profit attributable to shareholders was 34.48 million CNY, showing a year-on-year increase of 12.06% [2]. - The company's main business revenue is derived from pharmaceutical sales, accounting for 99.71% of total revenue, with other income contributing 0.29% [2]. Group 3: Shareholder Information - As of September 30, the number of shareholders for Jinhua was 20,100, a decrease of 2.22% from the previous period, with an average of 18,574 circulating shares per shareholder, which is an increase of 2.27% [2]. Group 4: Dividend Information - Since its A-share listing, Jinhua has distributed a total of 118 million CNY in dividends, with 10.58 million CNY distributed over the past three years [3].

Core Viewpoint - Tonghua Jinma's stock price has shown significant volatility, with a year-to-date increase of 76.31%, but a recent decline of 3.72% over the last five trading days [1] Group 1: Stock Performance - As of November 26, Tonghua Jinma's stock price was 27.68 CNY per share, with a market capitalization of 26.753 billion CNY [1] - The stock has experienced a trading volume of 73.0787 million CNY, with a turnover rate of 0.28% [1] - The company has appeared on the "龙虎榜" (a trading board for stocks with significant trading activity) twice this year, with the latest appearance on September 11, where it recorded a net buy of 142 million CNY [1] Group 2: Financial Performance - For the period from January to September 2025, Tonghua Jinma reported operating revenue of 892 million CNY, a year-on-year decrease of 7.88%, while net profit attributable to shareholders was 24.9635 million CNY, an increase of 4.35% [2] - The company's main business revenue composition includes biopharmaceuticals (59.27%), traditional Chinese medicine (40.56%), raw materials (0.10%), and others (0.07%) [1] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Tonghua Jinma was 38,200, a decrease of 3.20% from the previous period [2] - The top ten circulating shareholders include notable entities such as Innovation Drug and Southern CSI 1000 ETF, with varying changes in their holdings [3]

Group 1 - The stock price of Renmin Tongtai dropped by 2.00% on November 26, trading at 11.74 CNY per share, with a total market capitalization of 6.808 billion CNY [1] - Year-to-date, Renmin Tongtai's stock price has increased by 56.53%, but it has seen a decline of 26.39% over the last five trading days [1] - The company has appeared on the "Dragon and Tiger List" 13 times this year, with the most recent appearance on November 21, where it recorded a net buy of -7.5568 million CNY [1] Group 2 - Renmin Tongtai Pharmaceutical Co., Ltd. was established on February 19, 1994, and is primarily engaged in pharmaceutical wholesale, retail, and medical services [2] - The company's revenue composition includes 57.72% from wholesale to medical clients, 22.26% from wholesale to commercial clients, and 18.91% from retail [2] - As of September 30, the number of shareholders increased to 27,700, with an average of 20,900 circulating shares per shareholder [2] Group 3 - Renmin Tongtai has distributed a total of 1.671 billion CNY in dividends since its A-share listing, with 83.504 million CNY distributed in the last three years [3]

Core Insights - Qianjin Pharmaceutical's stock price increased by 2.01% on November 25, reaching 10.66 CNY per share, with a market capitalization of 5.247 billion CNY [1] - The company reported a revenue of 2.718 billion CNY for the first nine months of 2025, showing a year-on-year growth of 0.14%, and a net profit of 187 million CNY, up 11.47% year-on-year [2] - The company has distributed a total of 2.375 billion CNY in dividends since its A-share listing, with 449 million CNY distributed in the last three years [3] Company Overview - Qianjin Pharmaceutical, established on August 13, 1993, and listed on March 12, 2004, is located in Zhuzhou, Hunan Province [1] - The company's main business includes the research, production, and sales of traditional Chinese medicine, chemical drugs, and women's hygiene products, with revenue contributions of 39.95% from drug wholesale and retail, 28.33% from traditional Chinese medicine production, and 28.28% from Western medicine production [1] Shareholder and Market Activity - As of September 30, 2025, the number of shareholders decreased by 9.85% to 36,800, while the average circulating shares per person increased by 10.92% to 11,360 shares [2] - Major new institutional shareholders include Invesco Great Wall CSI Dividend Low Volatility 100 ETF and Tianhong CSI Dividend Low Volatility 100 ETF, among others [3]

Core Viewpoint - The stock of Kaikai Industrial has shown a slight increase of 2.03% on November 25, with a trading volume of 186 million yuan and a market capitalization of 3.966 billion yuan, despite a year-to-date decline of 0.50% [1] Financial Performance - For the period from January to September 2025, Kaikai Industrial reported a revenue of 825 million yuan, reflecting a year-on-year growth of 10.76%, while the net profit attributable to shareholders decreased by 62.81% to 12.8678 million yuan [2] - The company has cumulatively distributed 191 million yuan in dividends since its A-share listing, with 34.749 million yuan distributed over the last three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders for Kaikai Industrial was 33,700, a decrease of 7.03% from the previous period [2] - The top three circulating shareholders include China Merchants Securities (Hong Kong) Co., Ltd. with 1.1311 million shares, BOCI Securities Limited with 862,700 shares, and China Securities Shanghai State-owned Enterprise ETF (510810) with 787,500 shares, the latter having decreased its holdings by 164,200 shares compared to the previous period [3] Stock Performance - The stock has experienced a 4.86% increase over the last five trading days, a 13.45% increase over the last 20 days, and an 8.95% increase over the last 60 days [1] - The stock has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on January 2, where it recorded a net buy of -11.2005 million yuan [1]

Core Viewpoint - Qidi Pharmaceutical has shown a significant stock price increase of 62.59% year-to-date, despite recent declines in the short term [1][2] Financial Performance - As of September 30, Qidi Pharmaceutical reported a revenue of 225 million yuan, representing a year-on-year growth of 3.97% [2] - The company experienced a net profit loss of 14.82 million yuan, but this reflects a year-on-year improvement of 47.91% [2] - The company has cumulatively distributed dividends of 97.39 million yuan since its A-share listing, with no dividends paid in the last three years [3] Stock Market Activity - On November 25, Qidi Pharmaceutical's stock price rose by 2.03%, reaching 11.56 yuan per share, with a trading volume of 15.03 million yuan [1] - The stock has seen a net inflow of 584,800 yuan from main funds, with large orders accounting for 17.62% of total purchases [1] - The company has appeared on the stock market's "Dragon and Tiger List" three times this year, with the most recent instance on July 16, where it recorded a net buy of -44.09 million yuan [1] Company Overview - Qidi Pharmaceutical, established on November 12, 1993, and listed on January 19, 1996, is based in Hunan Province and specializes in traditional Chinese medicine and Western pharmaceutical formulations [2] - The company's main business revenue composition includes 79.43% from traditional Chinese medicine products, 14.28% from Guangdong Xiantong products, and 5.98% from other sources [2] - The company operates within the pharmaceutical and biotechnology sector, focusing on traditional Chinese medicine [2]

Core Viewpoint - Qing Shan Paper Industry's stock has shown significant volatility, with a year-to-date increase of 35.79% but a recent decline of 12.63% over the past five trading days [1] Financial Performance - For the period from January to September 2025, Qing Shan Paper Industry reported a revenue of 1.768 billion yuan, a year-on-year decrease of 11.87% [2] - The net profit attributable to the parent company for the same period was 64.99 million yuan, down 25.07% year-on-year [2] Stock Market Activity - As of November 25, the stock price was 3.46 yuan per share, with a market capitalization of 7.753 billion yuan [1] - The stock has been on the "龙虎榜" (a trading list for stocks with significant trading activity) 14 times this year, with the latest appearance on October 20, where it saw a net buy of 51.29 million yuan [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 207,900, a rise of 113.93% from the previous period [2] - The average number of circulating shares per shareholder decreased by 53.26% to 10,640 shares [2] Dividend Distribution - Since its A-share listing, Qing Shan Paper Industry has distributed a total of 321 million yuan in dividends, with 175 million yuan distributed over the last three years [3] Business Segments - The company's main business segments include pulp industry (67.47% of revenue), pharmaceutical industry (15.32%), paper product processing (11.45%), and others [2]

Core Viewpoint - Xidian Pharmaceutical's stock price has shown fluctuations, with a year-to-date increase of 18.89% but a recent decline in the last five trading days by 4.10% [1] Company Overview - Xidian Pharmaceutical, established on March 21, 1990, and listed on February 23, 2022, is located in Jilin Province and specializes in the research, production, and sales of chemical pharmaceutical raw materials and formulations [1] - The company's main revenue sources are: Risperidone orally disintegrating tablets (54.15%) and Compound Ferrous Sulfate Folic Acid Tablets (45.13%), with other products contributing 0.72% [1] Financial Performance - For the period from January to September 2025, Xidian Pharmaceutical reported operating revenue of 189 million yuan, a year-on-year decrease of 1.89%, and a net profit attributable to shareholders of 33.14 million yuan, down 2.70% year-on-year [1] - As of September 30, the number of shareholders decreased by 2.91% to 7,863, while the average circulating shares per person increased by 2.97% to 7,426 shares [1] Market Activity - On November 25, Xidian Pharmaceutical's stock rose by 2.05% to 30.90 yuan per share, with a trading volume of 5.4471 million yuan and a turnover rate of 0.30%, resulting in a total market capitalization of 2.364 billion yuan [1] - The stock has experienced a decline of 1.65% over the past 20 days and 5.65% over the past 60 days [1] Dividend Information - Since its A-share listing, Xidian Pharmaceutical has distributed a total of 63.34 million yuan in dividends, with 52.83 million yuan distributed over the past three years [2]

Core Viewpoint - Huadong Medicine's stock price has shown a mixed performance in recent trading sessions, with a year-to-date increase of 22.30% but a decline of 2.39% over the last five trading days [1] Financial Performance - For the period from January to September 2025, Huadong Medicine achieved a revenue of 32.664 billion yuan, representing a year-on-year growth of 3.77% [2] - The net profit attributable to shareholders for the same period was 2.748 billion yuan, reflecting a year-on-year increase of 7.24% [2] Shareholder Information - As of September 30, 2025, the number of Huadong Medicine's shareholders decreased by 1.50% to 68,800, while the average number of circulating shares per person increased by 1.53% to 25,466 shares [2] - The company has cumulatively distributed 8.873 billion yuan in dividends since its A-share listing, with 3.771 billion yuan distributed over the last three years [3] Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the third-largest circulating shareholder, holding 52.004 million shares, an increase of 12.1653 million shares from the previous period [3] - China Securities Finance Corporation remains the fourth-largest shareholder with 22.1868 million shares, unchanged from the previous period [3] - Notable changes in holdings include a decrease of 4.3243 million shares for the fifth-largest shareholder, China Universal Healthcare Mixed A [3]